Catalyst Pharmaceuticals, Inc. provided revenue guidance for full year 2022. The Company forecasts 2022 full year total revenues to be in the range of between $195 million and $205 million, representing a 38%-45% increase in total revenues as compared to 2021.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
15.76 USD | +0.67% | +6.86% | -6.42% |
05:47pm | HC Wainwright Adjusts Catalyst Pharmaceuticals' Price Target to $26 From $24, Keeps Buy Rating | MT |
May. 09 | Transcript : Catalyst Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.42% | 1.85B | |
-2.61% | 88.47B | |
+3.55% | 40.71B | |
-14.07% | 32.43B | |
+55.89% | 24.28B | |
-16.04% | 15.52B | |
-41.29% | 12.17B | |
-15.69% | 12.01B | |
-11.75% | 12B | |
+7.87% | 8.87B |
- Stock Market
- Equities
- CPRX Stock
- News Catalyst Pharmaceuticals, Inc.
- Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for Full Year 2022